Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma

HOUSTON, Oct. 24, 2014 /PRNewswire/ -- Burzynski Research Institute, Inc. (BRI) announced today that the U.S. Food and Drug Administration (FDA) has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). Study subjects will be placed in one of five treatment groups based on their age and whether or not they have received prior treatment for DIPG. The primary study endpoint is a decrease in the size of the tumor, either a partial response (≥ 50% decrease in the size of the tumor) or a complete response (disappearance of the tumor). The study is in its final organizational stage and will begin accruing patients as soon as this organizational stage is completed.

DIPG is primarily a disease of childhood, with the majority of patients being between 5 and 10 years of age. However, infants and adults can also be affected. It is the most common brainstem tumor in children, representing 75-80% of childhood brainstem tumors, and affecting an estimated 300 children in the U.S. each year. The prognosis for children with DIPG is significantly worse than that of other primary brainstem tumors. The standard of care for patients with newly-diagnosed DIPG is radiation therapy (RT), which appears to control tumor growth for a short period of time, prolonging survival by approximately 3 months. Within 3-8 months after completion of RT, most patients with DIPG will show progression of their disease. No chemotherapeutic agent has ever demonstrated a significant improvement in outcome beyond that achieved by RT alone. An original Burzynski Clinic paper, "The response and survival of children with recurrent intrinsic pontine glioma based on a phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma" was published with open access at Springerlink.com on April 10, 2014 (Childs Nerv Syst DOI 10.1007/s00381-014-2401-z).

About Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles. Research and development efforts are focused on basic research and phase 2 and 3 clinical trials, particularly in the treatment of brain tumors and other forms of cancer.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and further events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to an ability to use Antineoplastons A10 and AS2-1. Burzynski Research Institute, Inc. does not undertake to update any such forward-looking statements or to publically announce developments or events relating to the matters described herein.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/burzynski-research-institute-inc-announces-fda-permission-to-launch-a-new-clinical-trial-in-diffuse-intrinsic-brainstem-glioma-940500516.html

SOURCE Burzynski Research Institute, Inc.

Related Links

http://www.burzynskiclinic.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED